WEST LAFAYETTE, Ind., Oct. 20, 2020 (GLOBE NEWSWIRE) — Bioanalytical Methods, Inc. (NASDAQ:BASI) (“Inotiv”, the “Firm”, “We” or “Our”), doing enterprise as Inotiv, a number one supplier of drug discovery and growth companies, introduced at present that Andrew N. Alexander, DVM, Ph.D., MBA, DABT, has joined the Firm as Vice President, Pharmacology and Toxicology Operations, efficient October 19, 2020.
“Andy brings a skillset that may assist us develop Inotiv by offering broader experience to our purchasers,” stated Joe Flynn, the Firm’s Chief Industrial Officer. “No less than as importantly, Andy embraces our core values, particularly delivering wonderful consumer experiences. I’m excited to work with Andy right here at Inotiv.”
Don Maul, Sr. Vice President of Surgical Fashions, added, “Andy has a substantial amount of expertise and appreciable experience not solely with pharm/tox research, but in addition with designing and supporting research within the medical system sector, with an emphasis on advanced infusion research.”
Previous to becoming a member of Inotiv, Dr. Alexander established a popularity as a frontrunner in contract analysis organizations the place he labored in roles of accelerating duty for greater than a decade, offering scientific experience and examine path to purchasers. He then based his personal firm, Scientific Enterprise Advisors, which offered scientific and regulatory consulting to biopharmaceutical, veterinary, and medical system corporations. His credentials and coaching embody a Physician of Veterinary Medication, Ph.D. and MBA, and a postdoctoral fellowship in oncology and immunology, all from or on the College of Wisconsin, in addition to a surgical internship on the College of Veterinary Medication on the College of Illinois.
“I’m honored to affix Inotiv,” stated Dr. Alexander. “Being a part of an organization that’s sufficiently small to be versatile and responsive, however giant sufficient to supply a complete suite of companies aligns completely with my customer support focus.”
In regards to the Firm
Bioanalytical Methods, Inc., working as Inotiv, is a pharmaceutical discovery and growth firm offering contract analysis companies and monitoring devices to rising pharmaceutical corporations and the world’s main drug growth corporations and medical analysis organizations. The Firm focuses on creating revolutionary companies supporting its purchasers’ discovery and growth targets for improved decision-making and accelerated purpose attainment. The Firm’s merchandise deal with growing effectivity, enhancing knowledge, and lowering the price of taking new medicine to market. Go to inotivco.com for extra details about the Firm.
This launch might comprise forward-looking statements which are topic to dangers and uncertainties together with, however not restricted to, dangers and uncertainties associated to adjustments out there and demand for our services, the event, advertising and marketing and gross sales of services, adjustments in expertise, business and regulatory requirements, the timing of acquisitions and the profitable closing, integration and enterprise and monetary influence thereof, the influence of COVID-19 on the financial system, demand for our companies and merchandise and our operations, together with the measures taken by governpsychological authorities to handle the pandemic, which can precipitate or exacerbate different dangers and/or uncertainties and numerous different market and working dangers, together with these detailed within the Firm’s filings with the U.S. Securities and Trade Fee.
|FOR MORE INFORMATION:||Firm Contact:|
|Beth A. Taylor|
|Chief Monetary Officer|